Theravance Biopharma, Inc. (TBPH) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
TBPH's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
TBPH Revenue Analysis (2013–2024)
As of March 2, 2026, Theravance Biopharma, Inc. (TBPH) generated trailing twelve-month (TTM) revenue of $80.3 million, reflecting strong growth of +18.5% year-over-year. The most recent quarter (Q3 2025) recorded $20.0 million in revenue, down 23.7% sequentially.
Looking at the longer-term picture, TBPH's 5-year compound annual growth rate (CAGR) stands at -2.6%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $73.4 million in 2019.
Revenue diversification analysis shows TBPH's business is primarily driven by YUPELRI Monotherapy (56%), and Collaboration revenue (44%). With over half of revenue concentrated in YUPELRI Monotherapy, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including UTHR (+10.6% YoY), ZLAB (+15.3% YoY), and AMRN (-6.2% YoY), TBPH has underperformed the peer group in terms of revenue growth. Compare TBPH vs UTHR →
Peer Comparison
Compare TBPH's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TBPHCurrent | $80M | +18.5% | -2.6% | -72.9% | |
| UTHR | $3.2B | +10.6% | +16.5% | 46.9% | |
| ZLAB | $460M | +15.3% | +56.5% | -49.9% | |
| AMRN | $229M | -6.2% | -11.9% | -40.2% | |
| ALKS | $1.5B | -5.2% | +7.3% | 17.2% | |
| ADMA | $426M | +27.6% | +70.8% | 32.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $64.4M | +12.1% | $64.4M | 100.0% | $-46,949,000 | -72.9% |
| 2023 | $57.4M | +11.8% | $16.8M | 29.3% | $-56,035,000 | -97.6% |
| 2022 | $51.3M | -7.2% | $-12,046,000 | -23.5% | $-91,957,000 | -179.1% |
| 2021 | $55.3M | -23.0% | $-138,346,000 | -250.1% | $-257,784,000 | -466.1% |
| 2020 | $71.9M | -2.1% | $71.9M | 100.0% | $-297,627,000 | -414.2% |
| 2019 | $73.4M | +21.6% | $73.4M | 100.0% | $-251,915,000 | -343.1% |
| 2018 | $60.4M | +292.4% | $59.7M | 98.8% | $-238,751,000 | -395.5% |
| 2017 | $15.4M | -68.4% | $9.4M | 60.8% | $-260,123,000 | -1690.6% |
| 2016 | $48.6M | +15.5% | $45.8M | 94.1% | $-180,467,000 | -371.0% |
| 2015 | $42.1M | +260.4% | $37.5M | 88.9% | $-181,899,000 | -431.8% |
See TBPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TBPH Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare TBPH vs AGIO
See how TBPH stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is TBPH's revenue growth accelerating or slowing?
TBPH revenue is accelerating at +18.5% year-over-year, exceeding the 5-year CAGR of -2.6%. TTM revenue reached $80M. Growth momentum has increased versus prior periods.
What is TBPH's long-term revenue growth rate?
Theravance Biopharma, Inc.'s 5-year revenue CAGR of -2.6% reflects the sustained expansion pattern. Current YoY growth of +18.5% is above this long-term average.
How is TBPH's revenue distributed by segment?
TBPH reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.